Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

Guardant Health Announces Appeal Of Delaware District Court Final Judgment In TwinStrand Patent Suit, With Execution And Royalty Collection Stayed Pending Appeal

Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech

Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.

Guardant Health shares are trading lower after the U.S. District Court for the District of Delaware ruled in favor of TwinStrand and the University of Washington in their patent infringement lawsuit against the company.